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Interferon-stimulated genes (ISG)We have previously described a temporal regulation of host cell gene expression during adenovirus type 2
infection (Ad2) of primary human ﬁbroblasts. Among the eleven percent of genes deregulated by Ad2, a large
fraction included genes involved in cell cycle, growth control and antiviral defense, consistent with the
capacity of Ad2 to efﬁciently master the infected cell and cause an effectively productive infection.
Adenovirus type 12 (Ad12), which belongs to the highly oncogenic subgroup, is characterised by slow
progression, less cytopathic effect and lower virus yield compared to the non-oncogenic Ad2. Microarray
analysis of host cell gene expression in Ad12 infected human lung ﬁbroblasts (IMR90) demonstrated a
quantitatively and qualitatively less impact on host cell gene expression, compared to Ad2. Of the relatively
few genes up regulated during the course of Ad12 infection only two (5%) were identiﬁed as potential E2F
targets, compared to the signiﬁcant activation of E2F-dependent transcription observed during an Ad2
infection. Although approximately 30% of the genes deregulated by Ad12 were previously identiﬁed in Ad2-
infected cells, a distinct difference was observed in a group of interferon-stimulated genes (ISGs). G1P2, IFI6,
IFI16, IFIT1, IFIT2, IFITM1 and IRF9 were activated during the very late stage of infection, and a consistent
induction of IFNβ gene expression, preceding induction of the ISGs, was demonstrated by quantitative real-
time PCR analysis. An activated JAK/STAT signalling pathway was also indicated by the accumulation of all
components (STAT1, STAT2 and IRF9) of the ISGF3 transcription factor. Signiﬁcantly, none of these ISGs was
activated in Ad2 infected IMR90 cells. Thus, the inability of Ad12 to evade the interferon response might
explain its restricted virulence.
© 2009 Elsevier Inc. All rights reserved.Introduction
Over 50 immunologically distinct types of human adenovirus have
so far been identiﬁed. Infections are primarily associated with
respiratory illness, but depending on serotype a variety of illnesses
such as gastroenteritis, conjunctivitis and cystitis commonly occur. At
least some serotypes are capable of causing persistent infections, but
so far there is no evidence for the involvement of adenovirus in cancer
development in humans.
In contrast, adenovirus infection of non-permissive rodent cells in
vitro leads to transformation and a subset of human adenovirus
serotypes can also cause tumors in immunocompetent animals. The
oncogenic potential has been used to group human adenovirus into
six subgroups, where group A consists of the highly oncogenicC, Uppsala University, 751 24
and Systematics, EBC, Uppsala
l rights reserved.serotypes, such as adenovirus type 12 (Ad12) and group C consists of
non-oncogenic serotypes, such as Ad2 and Ad5.
Irrespectively of subgroup classiﬁcation, the capacity to transform
cells in vitro is encoded by the early transcription units E1A and E1B. The
E1B proteins prevent growth arrest and apoptosis through abrogating
the transcriptional activation by p53 (Wienzek et al., 2000) and by
mimicking the anti-apoptotic function of bcl-2 (Han et al., 1996).
Whereas Ad2/5 E1B 58K blocks p53 activity by enhancing proteasomal
degradation, the Ad12 E1B 54K interferes with p53 or p53-controlled
pathways, without forming a complex (van den Heuvel et al., 1993).
The adenovirus E1A gene encodes the major regulator of viral and
cellular gene expression and is as such essential for progression of the
infectious cycle. By comparing the amino acid sequence of E1A
between different adenovirus serotypes four conserved regions
(CR1–4) have been identiﬁed (Avvakumov et al., 2002, 2004).
Together with a less conserved amino-terminal sequence of E1A,
these regions harbour most of the regulatory activities of E1A. CR3
encodes the major activator of both viral genes and cellular genes
through binding to a variety of speciﬁc cellular transcription and basal
transcription factors (Akusjarvi, 1993; Flint and Shenk, 1997) as well
as targeting of the Mediator complex (Stevens et al., 2002; Wang and
Fig. 2. Numbers of differentially expressed cellular genes identiﬁed by cDNAmicroarray
analysis at indicated times during an Ad12 infection in IMR90 cells.
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members, thereby relieving inhibition of the transcription factor E2F
(Cobrinik,1996). The N-terminal region and CR1 interacts with several
transcriptional co-activators, including p300/CBP, p/CAF, p400 and
TRRAP (Arany et al., 1995; Deleu et al., 2001; Fuchs et al., 2001; Lang
and Hearing, 2003; Reid et al., 1998). Together, these protein
interactions activate viral gene expression and to force G0/G1 cells
to enter S-phase, thereby providing optimal conditions for viral DNA
replication. The CR4, located in the second exon of the E1A gene binds
to the cellular C-terminal binding protein (CtBP) (Boyd et al., 1993;
Chinnadurai, 2007; Schaeper et al., 1998). The binding of CtBP
enhances E1A dependent activation of transcription, possibly by
relieving CtBP dependent repression (Sundqvist et al., 1998, 2001).
However, CtBP may also exert a direct inhibition of CR1 dependent
transactivation (Sollerbrant et al., 1996).
The tumorigenic determinants of Ad12 have been correlated to a
number of speciﬁc characteristics of the Ad12 E1A proteins. The Ad12
E1A encodes a unique 52R protein (Brockmann et al., 1994), an amino-
terminal trans-activating function (Lipinski et al., 1997) and an
alanine-rich spacer segment between CR2 and CR3 (Jelinek et al.,
1994). In contrast to CR4 of Ad2/5 E1A, which hampers transformation
by E1A in cooperationwith an activated ras gene, CR4 of Ad12 E1A has
no impact on transformation (Williams et al., 2004).
Several cellular genes are differently expressed in cells trans-
formed by either Ad2/5 or Ad12. In particular, transcription of genes
involved in antigen presentation are down regulated in Ad12
transformed cells (Ackrill and Blair, 1988; Friedman and Ricciardi,
1988; Schrier et al., 1983). Repression of theMHC class I gene has been
investigated in particular detail and appears to be the result of a
concerted inhibition of NFκB binding to region I and recruitment of
the orphan nuclear repressor COUP-TFII to region II of the MHC
enhancer (Kushner et al., 1996). The diminished binding of NFκB to
DNA is caused by an E1A induced inhibition of phosphorylation of the
p50 subunit (Guan et al., 2008). Repression of the MHC class I
expression is enhanced by an over expression of COUP-TFII in Ad12
transformed cells (Smirnov et al., 2001) and an increased recruitment
of a histone deacetylase-containing corepressor complex to the
enhancer region II (Zhao and Ricciardi, 2006). Chromatin immuno-
precipitation analysis also demonstrated that Ad12 E1Awas present in
the DNA bound complex (Zhao and Ricciardi, 2006). Notably, a CtBP
interacting protein, CtIP, interacts with members of the COUP-TF
family (Avram et al., 2000), suggesting that CtBP might contribute to
the repression of the MHC class I. Although the reduced expression of
MHC class I genes helps Ad12 tumorigenic cells to escape killing by
cytotoxic T lymphocytes, this is not sufﬁcient to confer tumorigenicity
(Jelinek et al., 1994; Pereira et al., 1995).
Through several distinct routes the infected host cell can recognise
different viral components and as a consequence turn on expression of
IFNβ. Consecutively, this leads to activation of the JAK/STAT pathway
and a boost in expression of several IFN-stimulated genes (ISGs), all
with different tasks to combat the infecting virus. Almost all viruses
have developed multiple evasion strategies to circumvent the IFN
response (Randall and Goodbourn, 2008). Common for adenovirusesFig. 1. Progression of Ad12 infection in IMR90 cells. Levels of Ad12 E1A mRNA and
CCNE1 mRNA were determined by QRT-PCR using E1A- or CCNE1-speciﬁc primers.
Accumulation of Ad12 DNA was determined by Q-PCR using E1A-speciﬁc primers.is the ability to block the double stranded RNA inducible protein
kinase (PKR), by the virus encoded VA RNAI. In addition, E1A blocks
activation of both IFNβ and the downstream ISGs by its ability to
sequester p300/CBP (Ackrill et al., 1991; Bhattacharya et al., 1996;
Juang et al., 1998; Kalvakolanu et al., 1991). Recently it was also
reported that E4 ORF3 suppresses the IFN-induced antiviral state by
rearranging the nuclear POD structures (Ullman et al., 2007). Possible
differences between different adenovirus serotypes with regard to
interferon induction have not been thoroughly addressed, but at least
the E4 ORF3 activity is conserved between divergent serotypes,
including Ad12 (Ullman et al., 2007).
In a series of experiments, we have analysed changes in cellular
gene expression following infection with Ad2 or Ad12 (Dorn et al.,
2005; Granberg et al., 2005, 2006; Zhao et al., 2003, 2007). Ad12
causes a slower progression of infection, is less cytopathic and
produces lower virus yields. It was therefore not surprising that
signiﬁcantly fewer genes were altered during the course of an Ad12
infection in HeLa cells compared to an Ad2 infection (Dorn et al.,
2005). Still, more than 55% of the genes affected by Ad12 were also
changed by an Ad2 infection. Since an essential part of adenovirus-
induced changes is aimed at forcing cells into the S-phase, a majority
of target genes might not be detected during an infection of
unsynchronised HeLa cells. Here we demonstrate a more pronounced
regulation of cellular genes following Ad12 infection of growth
arrested primary human ﬁbroblasts. In agreement with previous
results from Ad12 infected HeLa cells, a signiﬁcant activation of
interferon-regulated genes was observed.
Results
Progression of Ad12 infection in human primary lung ﬁbroblast
Previously, we have examined the temporal changes in cellular
gene expression during the course of an Ad2 infection in human
primary lung ﬁbroblast (IMR90) using cDNA microarray analysis
(Zhao et al., 2007). The time points for analysis were selected
according to the progression of the lytic cycle, based on expression of
Ad E1A and cellular cyclin E1, as well as the replication of viral DNA.
Since Ad12 is known to have a delayed infection cycle compared to
Ad2, a similar analysis was performed using time points from 6 hours
post infection (hpi) up to 66 hpi (Fig. 1). Quantitative real-time PCR
(QRT-PCR) showed that expression of E1A began between 18 and
24 hpi and continued to increase following the progression of
infection. Expression of cyclin E1 followed the start of E1A accumula-
tion, but reached a maximum at 36 hpi and declined thereafter. The
maximal expression of cyclin E1 indicated that the infected cell had
progressed over the G1/S border and in agreement correlated with the
onset of viral DNA replication. Thus, the late phase of infection started
Table 1
Genes deregulated during the course of an Ad12 infection in IMR90 cells.
Category/gene name Clone ID Symbol 6 h 18 h 30 h 66 h Ad2/12a
Biosynthesis
2,3-bisphosphoglycerate mutase 430614 BPGM −1.0 NAb −1.9 −2.3 D/D
6-phosphogluconolactonase 797025 PGLS −1.1 1.1 1.2 −1.8 U/D
Procollagen-proline, 2-oxoglutarate 4-dioxygenase, beta 132702 P4HB 1.3 1.1 1.1 −1.8 S/D
Fatty acid desaturase 2 878174 FADS2 1.3 −1.5 −1.8 1.1 U/D
Enolase 1, (alpha) 1637756 ENO1 1.2 1.2 1.3 −1.9 NA/D
Xylosyltransferase I 41432 XYLT1 1.2 −1.3 −1.9 −2.4 D/D
Phosphatidylinositol glycan anchor biosynthesis 795947 PIGB 1.2 1.0 −2.0 −1.1 NA/D
Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3 1505469 PLOD3 1.2 1.1 −2.3 −1.3 S/D
Annexin A5 1864584 ANXA5 1.2 1.0 1.0 −1.9 NA/D
Succinate dehydrogenase complex, subunit A 80915 SDHA 1.9 NA −1.8 −2.4 D/D
5′-nucleotidase, ecto (CD73) 42070 NT5E 1.4 1.2 −1.2 −1.9 NA/D
CTP synthase 46182 CTPS 1.5 −1.0 −1.1 −2.0 S/D
Guanosine monophosphate reductase 753775 GMPR 1.8 1.1 1.1 −1.2 S/D
Alkaline phosphatase, intestinal 626967 ALPI 1.0 1.3 1.7 2.0 S/U
Leprecan-like 1 1472797 LEPREL1 1.4 −1.1 −4.5 −1.8 S/D
Chaperonin containing TCP1, subunit 8 2542182 CCT8 1.1 1.0 1.1 −1.9 NA/D
Eukaryotic translation initiation factor 1 2576857 EIF1 −1.0 −1.1 −1.2 −2.0 NA/D
Eukaryotic translation initiation factor 5 884867 EIF5 1.2 1.1 −1.1 −1.9 S/D
Mitochondrial ribosomal protein S6 785819 MRPS6 1.1 NA −2.1 −1.2 NA/D
Pepsinogen 3 group I (pepsinogen A) 155768 PGA3 −1.1 NA −1.2 4.1 S/U
Protease, serine, 12 (neurotrypsin, motopsin) 1553054 PRSS12 −1.0 NA 1.2 1.8 NA/U
Ribosomal protein L10 66686 RPL10 −1.1 −1.2 −1.2 −1.8 D/D
Ribosomal protein L29 2570895 RPL29 −1.1 1.0 −1.0 −1.8 NA/D
Ribosomal protein L35 877835 RPL35 −1.3 1.1 −1.0 −2.0 S/D
Ribosomal protein L7a 51981 RPL7A −1.2 −1.2 −1.1 −1.9 S/D
Ribosomal protein L9 2577249 RPL9 1.1 −1.0 1.0 −1.9 NA/D
Ribosomal protein S16 853151 RPS16 −1.0 −1.1 −1.1 −2.0 NA/D
Ribosomal protein S23 291974 RPS23 −1.1 −1.1 −1.1 −1.8 NA/D
Tyrosyl-tRNA synthetase 1470023 YARS 1.1 −1.0 −1.2 −1.9 NA/D
Ubiquitin carboxyl-terminal esterase L1 878833 UCHL1 1.2 1.3 1.2 −1.8 S/D
Ubiquitin-conjugating enzyme E2D 3 361097 UBE2D3 1.1 1.0 1.1 −1.8 S/D
Asparagine synthetase 1493527 ASNS −1.1 1.4 1.8 1.1 U/U
Sulﬁredoxin 1 homolog 178805 SRXN1 −1.0 NA −1.4 −2.1 D/D
Cell growth — apoptosis
Caspase 9, apoptosis-related cysteine peptidase 705110 CASP9 1.2 1.1 −1.0 −1.8 NA/D
FK506 binding protein 8, 38 kDa 2545242 FKBP8 −1.0 1.1 −1.8 −1.5 NA/D
GLI pathogenesis-related 1 (glioma) 260696 GLIPR1 1.2 1.1 −1.0 −1.9 NA/D
Homeodomain interacting protein kinase 2 294496 HIPK2 −1.1 −1.0 −1.1 −1.8 D/D
Mdm2, transformed 3T3 cell double minute 2 147075 MDM2 1.2 −1.2 −1.6 −4.5 D/D
Mitogen-activated protein kinase kinase 3 45641 and 1358393 MAP2K3 1.1 −1.3 −1.4 −1.9 D/D
Phosphoprotein enriched in astrocytes 15 725630 PEA15 1.2 1.1 1.0 −1.9 S/D
Poly (ADP-ribose) polymerase family 66815 PARP14 NA NA NA 1.9 D/U
Tumor necrosis factor receptor superfamily 1759582 TNFRSF12A 1.0 −1.4 −2.3 −2.8 NA/D
Cell growth — cell cycle
BTG3 associated nuclear protein 68652 BANP 1.4 NA −2.1 −2.1 S/D
Cyclin D1 841641 CCND1 1.2 −1.1 −1.1 −1.8 NA/D
Proliferating cell nuclear antigen 789182 PCNA −1.1 1.3 1.8 1.2 U/U
Tyrosine 3/tryptophan 5-monooxygenase activation protein 784129 YWHAG 1.0 −1.1 1.1 −1.8 D/D
WD repeat domain 68 2465039 WDR68 −1.0 −1.0 −1.3 −2.6 NA/D
V-fos FBJ murine osteosarcoma viral oncogene homolog 811015 FOS −1.1 1.1 −1.1 2.4 NA/U
V-myc related oncogene, opposite strand 1031203 MYCNOS 1.1 1.0 −1.1 −1.8 S/D
Cell growth — signal transduction
A kinase (PRKA) anchor protein (yotiao) 9 858540 AKAP9 −1.1 1.1 −1.8 −1.6 NA/D
ADP-ribosylation factor-like 4C 712139 ARL4C 1.2 NA NA −1.8 NA/D
Adrenomedullin 774446 ADM 1.1 1.4 1.5 1.9 S/U
Paralemmin 2 1467868 PALM2-AKAP2 1.2 −1.1 −2.0 −1.2 D/D
KN motif and ankyrin repeat domain 1 245272 KANK1 1.3 1.2 −1.0 −2.1 NA/D
Ankyrin repeat domain 46 449112 ANKRD46 1.1 1.0 1.1 −2.1 NA/D
ATPase, aminophospholipid transporter-like 1908734 ATP8A2 −1.1 −1.1 1.0 −1.8 NA/D
Calcium/calmodulin-dependent protein kinase II inhibitor 1 503602 CAMK2N1 1.0 −1.2 −1.2 −1.8 D/D
Calmodulin 2 (phosphorylase kinase, delta) 2577949 CALM2 1.0 −1.0 −1.1 −2.0 NA/D
Calpastatin 591381 CAST 1.1 NA −1.6 −2.2 NA/D
Chimerin (chimaerin) 1 898258 CHN1 1.2 −1.1 −1.2 −1.9 S/D
Dickkopf homolog 1 669375 DKK1 −1.0 −1.4 −2.4 −2.6 D/D
Dickkopf homolog 3 760299 DKK3 1.1 1.1 −1.0 −1.9 S/D
Fibroblast growth factor receptor 4 784224 FGFR4 1.1 1.2 1.3 −1.8 D/D
FK506 binding protein 1A, 12 kDa 745496 FKBP1A 1.1 −1.0 1.1 −2.1 NA/D
G protein-coupled receptor kinase 6 724932 GRK6 −1.1 NA −1.1 −1.8 D/D
G protein-coupled receptor 595037 GPRC5A NA NA 1.4 1.8 S/U
Glycoprotein A33 (transmembrane) 510542 GPA33 −1.3 −1.0 −1.4 −2.4 S/D
Gremlin 1, cysteine knot superfamily, homolog 324690 GREM1 1.3 −1.3 −1.2 −3.5 D/D
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Table 1 (continued)
Category/gene name Clone ID Symbol 6 h 18 h 30 h 66 h Ad2/12a
Cell growth — signal transduction
Inhibin, beta A 269815 and 2458975 INHBA −1.1 −1.8 −2.5 −2.5 D/D
Integrin, alpha 2 811740 ITGA2 1.2 1.0 −1.4 −2.3 D/D
KiSS-1 metastasis-suppressor 812955 KISS1 1.2 −1.3 −3.0 −2.5 NA/D
LIM and senescent cell antigen-like domains 1 2402904 LIMS1 1.1 −1.1 −1.3 −1.8 NA/D
Phosphatidylinositol 4-kinase, catalytic, alpha 731029 PIK4CA NA NA NA 3.3 S/U
RAB1A, member RAS oncogene family 150221 RAB1A 1.0 −1.1 −1.3 −1.8 NA/D
RAP1B, member of RAS oncogene family 897961 RAP1B 1.2 1.1 −1.1 −1.9 D/D
Regulator of G protein signalling 4 22355 and 2516356 RGS4 −1.1 −2.5 −3.3 −3.2 D/D
SH3 and PX domains 2A 505904 SH3PXD2A 1.2 −1.1 1.1 −1.8 D/D
SMAD speciﬁc E3 ubiquitin protein ligase 2 754026 SMURF2 1.3 −1.0 −1.2 −1.8 D/D
SMAD, mothers against DPP homolog 3 2028031 SMAD3 1.1 −1.5 −1.8 −1.3 NA/D
Stanniocalcin 2 823578 STC2 2.0 1.3 −1.9 −1.1 S/D
Transmembrane 4 L six family member 1 840567 TM4SF1 1.1 1.0 −1.0 −1.9 D/D
Vascular endothelial growth factor C 45138 VEGFC 1.1 −1.4 −2.0 −2.1 D/D
WD repeat domain 26 1493205 WDR26 −1.1 −1.1 −1.8 −1.4 NA/D
WNT1 inducible signalling pathway protein 2 2490795 WISP2 −1.0 −1.1 −1.1 −2.2 NA/D
Cysteine and glycine-rich protein 1 2465022 CSRP1 −1.2 −1.1 −1.3 −2.3 NA/D
Cell structure — cytoskeleton
Actin related protein 2/3 complex, subunit 4 2499797 ARPC4 1.2 1.1 −1.1 −1.9 NA/D
Cadherin 2, type 1, N-cadherin (neuronal) 325182 CDH2 −1.2 1.1 1.1 −1.8 S/D
Coactosin-like 1 (Dictyostelium) 325370 COTL1 1.2 −1.6 −1.4 −2.0 D/D
Desmin 2490569 DES 1.2 1.1 1.1 −1.9 NA/D
Enabled homolog (Drosophila) 758293 and 1627806 ENAH 1.4 −1.4 −1.7 −2.3 D/D
FERM domain containing 6 796152 FRMD6 1.2 −1.2 −1.5 −2.2 D/D
LIM and SH3 protein 1 1631663 LASP1 1.2 1.1 1.1 −1.8 D/D
Microtubule associated monoxygenase, calponin, LIM domain 786265 MICAL2 1.0 NA −1.8 −2.0 D/D
Myosin X 2052032 MYO10 1.1 −1.3 −2.1 −1.4 NA/D
Nestin 266135 and 1470278 NES 1.1 −1.0 −1.4 −1.8 S/D
Palladin, cytoskeletal associated protein 2542582 PALLD 1.3 −1.1 −1.1 −2.0 NA/D
PDZ and LIM domain 7 (enigma) 502682 PDLIM7 1.2 −1.1 −1.3 −2.0 D/D
Retinoic acid induced 14 823850 RAI14 1.3 −1.0 −1.2 −2.0 D/D
Thymosin, beta 4, X-linked 1895357 and 868368 TMSB4X 1.1 −1.2 −1.4 −2.8 D/D
Tubulin, beta 2C 1492104 TUBB2C 1.1 1.2 1.1 −1.9 NA/D
Vimentin 840511 VIM 1.2 1.2 1.1 −2.0 D/D
Cell structure — extracellular
Fibronectin 1 256820 FN1 1.3 −1.1 −2.3 −1.6 NA/D
Matrix metallopeptidase 1 (interstitial collagenase) 589115 MMP1 −1.1 1.1 −1.1 −1.9 NA/D
Microﬁbrillar-associated protein 4 759163 MFAP4 1.2 −1.1 −1.1 −1.9 S/D
Plasminogen activator, urokinase receptor 2421798 PLAUR −1.0 −1.1 −1.5 −1.8 NA/D
Pregnancy speciﬁc beta-1-glycoprotein 4 141677 PSG4 1.0 −1.2 −1.9 −1.6 D/D
Serpin peptidase inhibitor, member 2 70692 SERPINB2 1.1 1.6 1.8 1.2 U/U
Serpin peptidase inhibitor, member 1 244307 SERPINE1 1.2 −1.5 −2.2 −2.5 D/D
Tenascin C (hexabrachion) 23185 and 2577230 TNC 1.3 1.0 −1.2 −1.9 D/D
Thrombospondin 1 666371 THBS1 1.1 −1.7 −2.3 −2.9 D/D
Collagen, type I alpha 153646 COL1A1 1.2 −1.1 −1.6 −3.0 D/D
Defense — heat shock
AHA1, activator of heat shock 90 kDa protein ATPase homolog 1 754649 AHSA1 1.2 −1.0 −1.1 −1.8 NA/D
Heat shock 60 kDa protein 1 (chaperonin) 2565316 HSPD1 1.1 1.2 1.1 −1.9 NA/D
Heat shock 70 kDa protein 1-like 50615 HSPA1L 1.2 −1.4 −1.6 −2.6 D/D
Heat shock 70 kDa protein 8 884719 HSPA8 1.3 −1.2 1.0 −2.0 NA/D
Heat shock protein 90 kDa alpha (cytosolic) 2577075 HSP90AB1 1.1 1.0 −1.0 −1.9 NA/D
Defense — interferon pathway
Deltex 3-like (Drosophila) 510845 DTX3L NA NA 1.3 2.0 NA/U
Interferon-induced transmembrane protein 1 (9–27) 510383 and 755599 IFITM1 −1.1 −1.1 −1.1 3.1 S/U
Interferon regulatory factor 5 260035 IRF5 1.5 NA −2.0 −2.6 S/D
Interferon, alpha-inducible protein (clone IFI-15K) 742132 G1P2 1.4 −1.1 1.1 3.4 S/U
Interferon, alpha-inducible protein 6 782513 IFI6 NA NA NA 2.9 S/U
Interferon-induced protein with tetratricopeptide repeats 1 823696 and 2550047 IFIT1 NA NA NA 6.8 NA/U
Interferon-induced protein with tetratricopeptide repeats 2 289496 IFIT2 NA NA −1.2 3.7 S/U
Interferon-stimulated transcription factor 3, gamma 48 kDa 724588 IRF9 NA NA NA 2.5 NA/U
Pyrin and HIN domain family, member 1 824602 PYHIN1 −1.3 NA 1.5 1.8 NA/U
Defense — stress
Chemokine (C–C motif) ligand 2 768561 CCL2 −1.2 −3.4 −1.9 −1.2 D/D
Metallothionein 1F (functional) 245990 MT1F −1.2 −1.2 −1.5 −2.2 U/D
Metallothionein 1G 2317017 MT1G −1.4 −1.1 −1.5 −2.7 NA/D
Metallothionein 1H 214162 MT1H −1.1 1.0 −1.3 −2.4 S/D
Metallothionein 2A 590150 and 1472735 and 1899230 MT2A −1.2 −1.2 −1.7 −2.6 NA/D
Dimethylarginine dimethylaminohydrolase 1 813187 DDAH1 1.2 −1.3 −1.2 −1.9 D/D
Dynein, light chain, LC8-type 1 853938 DNCL1 1.2 −1.0 −1.3 −2.9 D/D
Cardiotrophin 1 506583 CTF1 1.1 −1.1 −1.8 −1.5 NA/D
(continued on next page)
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Table 1 (continued)
Category/gene name Clone ID Symbol 6 h 18 h 30 h 66 h Ad2/12a
Defense — stress
Glutathione S-transferase omega 1 774036 GSTO1 −1.1 −1.1 1.0 −2.0 S/D
Hypoxia-inducible factor 1, alpha subunit 325117 HIF1A 1.5 1.1 −1.2 −2.0 NA/D
Lipocalin 2 (oncogene 24p3) 302127 LCN2 1.1 −1.2 1.0 −2.2 NA/D
CD1b molecule 1950782 CD1B 1.0 1.1 −1.9 −1.1 NA/D
Immunoglobulin lambda-like polypeptide 1 344134 IGLL1 1.3 −1.3 −1.3 −2.5 U/U
Gene expression — chromatin
Amine oxidase (ﬂavin containing) domain 1 133136 AOF1 −1.0 1.3 1.9 1.1 U/U
Histone cluster 1, H2bf 201125 HIST1H2BF NA NA 2.0 1.6 U/U
Histone cluster 1, H2bc 214006 HIST1H2BC −1.2 1.3 1.9 1.5 NA/U
Transcribed locus, strongly similar histone 2, H2, like 1675553 NA NA 1.9 1.4 U/U
MKI67 (FHA domain) interacting nucleolar phosphoprotein 788415 MKI67IP −1.2 −1.1 −1.3 −1.9 D/D
Mortality factor 4 like 2 2578251 MORF4L2 1.2 1.1 1.0 −2.2 NA/D
X (inactive)-speciﬁc transcript 470227 XIST 1.2 NA 1.9 NA U/U
Gene expression — RNA export
DEAD (Asp-Glu-Ala-As) box polypeptide 19B 1916839 DDX19B 1.2 −1.3 −1.7 −1.9 NA/D
DEAD (Asp-Glu-Ala-Asp) box polypeptide 21 2543348 DDX21 1.2 −1.2 −1.3 −1.9 NA/D
Gene expression — RNA processing
DAZ associated protein 1 2090142 DAZAP1 1.2 1.0 −1.9 −1.2 NA/D
RNA binding motif (RNP1, RRM) protein 3 380797 RBM3 1.1 −1.1 −1.2 −1.8 S/D
Splicing factor, arginine/serine-rich 3 173554 and 2577108 SFRS3 1.1 −1.0 1.0 −1.9 S/D
Gene expression — transcription
CAMP responsive element binding protein 3-like 1 325126 CREB3L1 1.2 1.2 −1.9 −1.2 S/D
C-terminal binding protein 1 347702 CTBP1 1.1 −1.2 −2.3 −1.5 S/D
Elongation factor, RNA polymerase II, 2 324672 and 2515861 ELL2 1.2 −1.2 −1.3 −2.3 D/D
Inhibitor of DNA binding 3 756405 ID3 −1.0 −1.4 −1.9 −4.3 D/D
Kruppel-like factor 2 (lung) 344648 KLF2 1.0 −1.5 −1.8 −2.7 NA/D
Polymerase I and transcript release factor 2392824 PTRF 1.2 1.1 −2.0 −1.7 NA/D
Pre-B-cell leukemia transcription factor 3 2306852 PBX3 −1.2 −1.3 −1.6 −2.2 NA/D
Transcription factor 19 (SC1) 416075 TCF19 NA NA 2.1 NA U/U
Tripartite motif-containing 28 853562 TRIM28 1.3 1.2 1.2 −1.8 S/D
Zinc ﬁnger protein 207 246869 ZNF207 1.1 −1.1 −1.1 −2.0 S/D
Other
Calcium binding protein 39 809422 CAB39 1.1 −1.2 −1.1 −1.9 D/D
Chromosome 1 open reading frame 144 376839 C1orf144 1.2 −1.2 −1.9 −1.6 NA/D
Chromosome 17 open reading frame 74 2009792 C17orf74 −1.2 1.3 −1.6 −1.8 NA/D
Coagulation factor VIII-associated (intronic transcript) 1 810264 F8A1 1.1 −1.0 −1.1 −1.9 S/D
Coiled-coil domain containing 94 897159 CCDC94 1.5 −1.5 −2.6 −2.9 D/D
CUB and Sushi multiple domains 2 2106859 CSMD2 1.4 1.1 −1.0 −2.6 NA/D
Ferritin, heavy polypeptide-like 19 1712407 FTHL11 1.2 −1.1 −3.6 −1.6 NA/D
Myelin basic protein 700681 MBP 1.0 NA −2.0 −1.6 NA/D
Pleckstrin homology-like domain, family B, member 1 772437 PHLDB1 −1.1 −1.1 −1.1 −1.9 D/D
Schlafen family member 11 239724 SLFN11 NA NA 1.8 NA NA/U
Shwachman–Bodian–Diamond syndrome pseudogene 77361 SBDSP −1.0 −1.0 −1.1 −1.9 S/D
Tetratricopeptide repeat domain 7A 153650 TTC7A NA NA NA 3.2 NA/U
WD repeat domain 12 1967136 WDR12 −1.2 1.4 −1.1 1.8 NA/U
Zinc binding alcohol dehydrogenase, domain containing 2 1679977 ZADH2 1.1 −1.2 −1.2 −1.9 NA/D
Unnamed
128511 −1.1 1.3 −1.0 1.8 NA/U
141854 −1.1 1.3 1.7 1.9 NA/U
1610469 1.1 1.0 −1.0 −2.3 D/D
125246 1.3 −1.2 −1.5 −2.2 NA/D
282468 1.2 −1.2 −1.1 −1.9 NA/D
190021 1.1 1.1 −1.4 −1.9 S/D
1553113 1.1 1.1 1.0 −1.9 NA/D
124661 1.6 1.1 −5.6 −1.9 NA/D
68225 1.2 1.0 1.0 −1.8 NA/D
2017295 1.4 1.1 −4.6 −1.6 NA/D
1627831 1.2 −1.0 −1.9 −1.6 NA/D
2112870 −1.2 1.6 −2.1 −1.4 NA/D
436420 1.7 −1.1 −7.0 −1.4 U/D
1913697 NA NA NA 1.9 NA/U
200711 −1.1 1.1 −1.1 1.8 NA/U
82122 1.2 1.3 1.2 −1.8 U/D
327079 −1.2 NA −2.1 1.6 NA/U
855177 NA NA 1.2 2.7 S/U
1837280 1.1 1.1 1.0 −2.7 NA/D
878631 1.3 −1.1 −1.8 −1.4 S/D
2515027 1.2 −2.3 NA −3.1 NA/D
1681920 1.0 −1.2 −1.2 −2.4 NA/D
202535 −1.2 −1.1 −1.8 −2.2 D/D
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Table 1 (continued)
Category/gene name Clone ID Symbol 6 h 18 h 30 h 66 h Ad2/12a
Unnamed
47043 1.1 −1.3 −1.8 −1.8 D/D
199945 1.1 −1.3 −1.6 −1.9 D/D
550141 −1.0 −1.3 −1.2 −2.5 D/D
344376 1.1 −1.4 −1.3 −2.1 D/D
284479 1.3 −1.1 −1.0 −1.9 D/D
34093 −1.1 1.0 −1.1 −1.9 NA/D
292399 NA NA 1.9 1.3 U/U
306575 1.1 −1.1 −1.1 −1.8 S/D
51973 1.2 1.0 1.0 −1.9 NA/D
897531 1.3 1.3 −1.0 −2.2 NA/D
360914 −1.0 −1.1 −1.0 −1.8 NA/D
110582 −1.1 NA −1.8 −1.2 S/D
256895 NA NA −1.1 1.8 NA/U
296679 −1.4 1.1 −1.1 −2.1 U/D
773479 1.2 1.3 1.1 −2.1 U/D
46463 1.0 −1.2 −1.3 −1.8 D/D
2461849 1.2 −1.0 −1.1 −1.8 NA/D
1733391 1.0 1.9 −1.6 −1.9 NA/D
1569263 1.3 1.0 −1.1 −1.8 NA/D
250868 −1.0 −1.1 −1.8 −1.5 NA/D
2029998 1.2 −1.2 −2.1 −1.1 NA/D
241824 −1.1 1.4 1.8 1.8 NA/U
82434 1.0 1.4 1.5 1.8 NA/U
1854617 NA NA 2.5 NA NA/U
283315 1.2 −1.7 −1.9 −1.4 D/D
Numbers in italics represents data with low intensity and/or high variation.
a Comparison of here presented data with data from Ad2 infected IMR90 cells (Zhao et al., 2007). U, up regulated; D, down regulated; S, similar expression level; NA, data not
available.
b NA (not available) denotes that data could not be obtained.
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most likely reﬂects the experimental inadequacy to detect viral DNA
packaged into new virus particles. Based on the determined progres-
sion of infection of Ad12 in the IMR90 cell line, a time course
experiment analysing cellular gene expression at 6, 18, 30 and 66 hpi
was carried out using microarrays containing 46000 cDNAs.
Deregulation of cellular gene expression during an Ad12 infection
Using a cut-off value of 1.8-fold, a total of 223 unique genes were
identiﬁed as differentially expressed during the course of the Ad12
infection compared to the uninfected control cells (Fig. 2). Consistent
with the delayed onset of early gene expression (Fig. 1), essentially no
changes of host cell gene expression were observed at the earliest
analysed time point, 6 hpi (Fig. 2), except for activation of a single
gene, GMPR (Table 1). At the second time point, 18 hpi, just as E1A
started to accumulate, two genes involved in cell signalling and
growth control were down regulated. RGS4 encodes a member of the
regulator of G protein signalling family and has a crucial role in
shutting off G protein-mediated responses by driving G proteins into
their inactive GDP-bound forms. INHBA encodes a member of theFig. 3. Functional classiﬁcation of differentially expressed cellular genes identiﬁed by cDTGFβ-superfamily and has antiproliferative activities. Both of these
genes continued to be repressed throughout the infectious cycle
(Table 1).
As the infection proceeded into the late phase, a progressive
increase in the number of deregulated genes occurred (Fig. 2). At the
onset of the late phase (30 hpi), thirteen genes were up regulated, of
which almost half are involved in nucleic acid metabolism
(HIST1H2BC, HIST1H2BF, PCNA, TCF19, AOF1, XIST), which is consistent
with the observed initiation of viral DNA replication at 30 hpi. In
parallel, 52 genes were repressed. From a viral perspective, repression
of several genes has positive implications on virus propagation; ID3,
CTBP and KLF2 encode transcriptional repressors, CTF1 and CCL2 are
defense cytokines, TNFSF12A and FKBP8 are linked to induction of
apoptosis, IRF5 is part of the virus-induced interferon response,
DAZAPmight regulate polyA-binding, SMAD3mediates TGFβ-induced
growth arrest, DKK1 can induce growth arrest through the Wnt
pathway and CREB3L1 is a membrane-associated transcription factor
sensing ER stress.
Toward the completion of the virus life cycle at 66 hpi, the number
of repressed genes increased to 151 and demonstrated a fairly even
distribution over all gene categories, although the largest increase wasNA microarray analysis at indicated times during an Ad12 infection in IMR90 cells.
Fig. 4. Western blot analysis of STAT1, STAT2, IRF9 and β-actin. Ad12 infected IMR90
cells were harvested at indicated times andmock-infected cells were harvested at 6 hpi.
Each lane contains 20 μg of total cellular protein.
192 H. Zhao et al. / Virology 392 (2009) 186–195seen for genes in growth control and cell structure (Fig. 3). Only 19 of
these genes were also repressed (N1.8 fold) at 30 hpi. Thus, the
majority of genes repressed at 66 hpi represented changes in cellular
gene expression inﬂicted at the very late stage of the virus life cycle
(Table 1). Finally, with the exception of one gene of unknown function
(Clone ID 241824, Table 1), the genes activated at 30 hpi were
repressed and were replaced by a group of 26 new genes activated at
66 hpi. These included two proteases, PRSS12 and PGA53, an alkaline
phosphatase ALPI and a polyADP ribose polymerase PARP14, possibly
indicating initiation of apoptosis.
Activation of the antiviral interferon-stimulated genes during the very
late phase of an Ad12 infection
Eight of the 26 cellular genes up regulated at 66 hpi are known
players in the cellular interferon (IFN) response. This suggested that
the Ad12 infection triggered activation of type I IFN, which subse-
quently activated the IFN-inducible genes (ISGs). Although expression
of type I IFN was not detected in the microarray analysis, RT-PCR
analysis demonstrated that IFNβ was activated from 18 hpi and
onwards, thus promoting activation of ISGs at 66 hpi (Table 2). A
robust activation of three of the identiﬁed ISGs, IF1T1, IRF9 and G1P2,
was conﬁrmed by RT-PCR (Table 2). Since ISG induction requires the
JAK/STAT pathway, we also analysed expression of STAT1 and STAT2.
Although activation of the STAT genes was not identiﬁed by
microarray analysis, a clear activation was demonstrated by RT-PCR
(Table 2). Notably, for two of the IFN-inducible genes IFIT1 and IFITM1,
two separate clones demonstrated consistent results (Table 2). In
summary, these results suggest that the IFN pathway was activated
during the very late phase of Ad12 infection.
Activation ISGs are consistent with enhanced accumulation of the
transcription factor ISGF3
To further conﬁrm the activation of the IFN pathway, the protein
levels of three key players of the IFN pathway, STAT1, STAT2 and IRF9,
were analysed byWestern blot analysis at 6, 18, 30 and 66 hpi. During
most part of the viral life cycle, the levels for all three genes were
similar, or slightly reduced, compared to mock-infected cells (Fig. 4).
Consistent with the increased mRNA accumulation at 66 hpi, a
signiﬁcant increase in protein levels was observed at 66 hpi (Fig. 4).
Ad12 demonstrates a restricted impact on host cell gene expression
compared to Ad2
Estimating that approximately 30% of the cDNAs on the array gave
detectable signals (without taking into account the presence of re-Table 2
Regulation of interferon response genes during an Ad12 infection.
RT-PCR Microarray
6 h 18 h 30 h 66 h 6 h 18 h 30 h 66 h
IFI6 –a – – – NSDb NSD NSD 2.9
IFI16 – – – – −1.3 NSD 1.5 1.8
IFIT2 – – – – NSD NSD −1.2 3.7
IFITM1 – – – – −1.1 −1.1 −1.0 2.3
IFITM1 – – – – −1.0 NSD −1.3 4.2
IFIT1 0.8 0.9 2.6 48.6 NSD NSD NSD 5.2
IFIT1 0.8 0.9 2.6 48.6 NSD NSD NSD 8.9
IRF9 0.9 1.2 1.9 11.7 NSD NSD NSD 2.5
G1P2 1.0 0.9 1.6 10.2 1.4 −1.1 1.1 3.4
IFNβ 0.9 3.9 4.7 1.8 NSD NSD NSD NSD
STAT1 1.2 1.1 1.6 4.5 −1.47 1.45 −1.09 1.03
STAT2 1.3 1.3 1.4 3.9 NSD NSD NSD 1.29
Numbers in italics represents data with low intensity and/or high variation.
a Not analysed.
b NSD, no signal detected.dundant cDNAs), the Ad12 regulated genes represent about 1.6% of all
expressed genes. In a similar study, approximately 11% of the detectable
host cell genes were deregulated (N2-fold) during the course of an Ad2
infection (Zhao et al., 2007). In addition, whereas only 15–20% of the
differentially regulated genes in Ad12 infected cells showed increased
expression (Fig. 2), between 30 and 42% of genes regulated byAd2were
activated (Zhao et al., 2007). Still, approximately 30% of the genes
demonstrating altered expression during the Ad12 infection were also
similarly changed by Ad2 (Table 1 and Zhao et al. (2007)). Consistent
results were speciﬁcally seen regarding the early down regulation of
RSG4 and INHBA, the similar up regulation of genes involved in
chromatin structure, replication and gene expression (PCNA, AOF1, XIST,
TCF19,HIST1H2BC andHIST1H2BF) and the regulation of genes involved
in cell structure where 50% of the repressed genes were also repressed
by Ad2. Although amajority of the remaining geneswere not identiﬁed
at all in the Ad2 analysis, three named genes were repressed by Ad12,
but activated by Ad2 (PGLS, FADS2 and MT1F), and one gene was
activated by Ad12, but repressed by Ad2 (PARP14, Table 1).
Discussion
From a molecular perspective, human adenovirus is among the
most intensely studied viruses. Although more than 50 different
serotypes exist, the highly similar Ad2 and Ad5 have been the target of
almost all detailed investigations of molecular mechanisms. During
the last decade, with an increasing focus on adenovirus for gene and
oncotherapy, less prevalent serotypes have gained interest. However,
this mainly concerns their tissue tropism and possible use as crippled
vectors. Consequently, relatively little is known about the speciﬁc
events during the lytic cycle of most adenoviruses, although it is
generally assumed that homologous genes play similar roles. Ad12
belongs to the highly oncogenic subgroup with a similar genome
organisation and a high overall sequence homology to Ad2/5(Sprengel
et al., 1994). It is therefore reasonable to assume that the Ad12
infectious cycle largely is identical to that of Ad2/5, although the time
frame for completion of the virus life cycle is extended for Ad12. In
earlier studies we have characterised the temporal alterations in
cellular gene expression proﬁles following infection of IMR90 cells
with Ad2. Brieﬂy, prior to the onset of viral gene expression a cellular
defense response is manifested through a transient activation of
several transcription factors involved in stress activated gene expres-
sion (Granberg et al., 2006). The expression of early viral genes is
paralleled by up and down regulation of cellular gene expression,
much of which is consistent with virus-induced changes optimizing
virus proliferation (Zhao et al., 2007). Finally, during the last phase of
the virus life cycle, down regulation of host gene expression becomes
most prevalent, including a signiﬁcant repression of genes involved in
cell structure (Zhao et al., 2007).
In this study, we have performed a comparable analysis using
Ad12-infected IMR90 cells. Approximately 30% of the genes regulated
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Ad12 had less impact on host cell gene expression compared to Ad2,
both with respect to the number of genes (1.6% versus 11% of all
detectably expressed genes, for Ad12 and Ad2, respectively) and the
magnitude of regulation. (Selected threshold value was 1.8-fold for
Ad12 and 2-fold for Ad2.) Moreover, whereas only 15–20% of the
deregulated genes in Ad12 infected cells showed enhanced expres-
sion, between 30 and 42% of genes deregulated by Ad2 were activated
(Zhao et al., 2007). A signiﬁcant fraction (17–28%) of the genes up
regulated during an Ad2 infection were potential E2F targets,
consistent with an E1A-dependent release of pRB inhibition of E2F.
Surprisingly, of the 13 genes found up regulated during the
corresponding time frame in Ad12 infected cells, only the HIST1H2B
and PCNA genes are identiﬁed as E2F target genes. This difference in
potency might reﬂect different activity or less efﬁcient expression of
Ad12 regulatory proteins. Notably, a similar difference between Ad12
and Ad2 in their ability to regulate host cell gene expression was
also observed following infection of HeLa cells (Dorn et al., 2005; Zhao
et al., 2003).
In this study, we were unable to detect the previously described
Ad12 repression of genes involved in antigen presentation (Ackrill and
Blair, 1988; Friedman and Ricciardi, 1988; Schrier et al., 1983).
Although we did observe down regulation of MHC class I expression
following Ad12 infection of HeLa cells using nylon ﬁlter macroarrays,
this was not observed when glass slide microarrays were used (Dorn
et al., 2005). Whether this discrepancy is due to deﬁciencies in the
speciﬁc MHC class I cDNAs printed on the glass slide microarrays
remains to be determined.
In this report we demonstrate a signiﬁcant up regulation of eight
ISGs (PYHIN1, DTX3L, IRF9, IFI6, IFITM1, G1P2, IFIT2, IFIT1) during the
late phase of the infection cycle. None of these was detected as Ad2
regulated genes (Zhao et al., 2007). The Ad12 induced ISGs validated
by RT-PCR were also examined by RT-PCR on RNA from Ad2 infected
cells. All genes showed extremely weak signal consistent with their
low abundance and lack of activation during Ad2 infection (data not
shown). To exclude the possibility that the observed activation of ISG
expression in Ad12 infected cells was due to only partial infection of
the cell culture, ISG expressionwasmeasured following infectionwith
increasing amounts of Ad12. At the maximal dose, 2000 particles per
cell, the activation of ISG expression was even stronger (data not
shown). Consistently, partially Ad2 infected IMR90 cell cultures still
failed to show activation of ISGs (data not shown), suggesting that the
observed stimulation of ISG expression is caused by an Ad12 speciﬁc
factor.
Most of the identiﬁed ISGs are known to inhibit viral infections.
IRF9 is the third subunit of the STAT-containing transcription factor
ISGF3 and essential for the IFNβ-induced expression of the ISGs. G1P2,
IFIT1 and IFIT2 are among the most highly induced ISGs (Randall and
Goodbourn, 2008). G1P2 (also called ISG15) encodes a ubiquitin-like
molecule, which after conjugation to several targets in the ISG family
leads to enhanced protein stability by preventing polyubiquitination
and degradation (Zhao et al., 2005). The antiviral activity of G1P2 has
been demonstrated for several viruses, including herpesvirus and
inﬂuenzavirus (Lenschow et al., 2007) and HIV (Okumura et al.,
2006). Interestingly, the highly pathogenic avian inﬂuenzavirus
induces signiﬁcantly less G1P2 expression compared to less virulent
strains (Zeng et al., 2007). IFIT1 and IFIT2 (also called ISG56 and
ISG54) are also induced upon infection with different viruses, such as
sendaivirus, encephalomyocarditisvirus, cytomegalovirus and lym-
phocytic choriomenigitis virus (Guo et al., 2000; Preston et al., 2001;
Wacher et al., 2007). Both genes are dependent on STAT1 and STAT2
(Wacher et al., 2007) and encode proteins with the capacity to inhibit
initiation of protein translation by binding to the translation initiation
factor eIF3 (Guo et al., 2000; Terenzi et al., 2005). Very little is known
about the DTX3L, but it belongs to a family of E3 ligases and has been
implicated in the ISG15ylation system (Klein et al., 2006). Althoughthe mechanism for the antiviral activity of the small proteins IFITM1
and IFI6 (17 kDa and 12.9 kDa, respectively) is unknown, expression of
both genes is repressed in HBV-expressing liver cells (Guan et al.,
2007), whereas HCV-expressing cells block IFI6 expression (Itsui et al.,
2006). For both viruses however, restoration of gene expression leads
to suppression of virus growth. Finally, PYHIN1 (also called IFI16)
encodes a transcriptional repressor, which is implicated in p53-
mediated growth control (Xin et al., 2004). Altogether, the activation
of these eight ISGs during the late stage of an Ad12 infection is
consistent with a cellular attempt to mount an antiviral defense, and
the inability of Ad12 to mobilise countermeasures. Thus, the resulting
antiviral state might be the reason for the reduced virulence of Ad12
compared to Ad2/5. However, it cannot be excluded that the virus
might exploit the enhanced expression of ISGs. For example, the
activated expression of PYHIN1 by mouse cytomegalovirus leads to
enhanced viral DNA synthesis (Rolle et al., 2001) and IFI6 can inhibit
intrinsic apoptosis (Cheriyath et al., 2007).
Although IFNβ expression was undetectable in the microarray
data, the more sensitive RT-PCR analysis demonstrated an up
regulated expression preceding the induced expression of ISGs,
consistent with IFNβ being the primary activator of the JAK/STAT
pathway. The RT-PCR analysis also demonstrated increased levels of
all three components of the ISGF3 transcription factor (STAT1, STAT2
and IRF9). These data indicate that IFNβ induction, which starts at
approximately the same time as viral DNA replication commences,
activates the JAK/STAT signalling cascade and proceeds with induction
of several ISGs. A further evidence for an active IFN signalling was the
concurrent increase in protein levels of all ISGF3 components at
66 hpi. In addition, this observation indicates that the E4 ORF6-
dependent inhibition of nuclear export of cellular mRNA described for
Ad2/5 (Tauber and Dobner, 2001) may not be completely functional in
Ad12 infected cells.
The most efﬁcient viral activator of IFNβ expression is dsRNA,
which during an adenovirus infection might arise from the symme-
trical transcription occurring during the late phase of infection
(Pettersson and Philipson, 1974). Brieﬂy, dsRNA activates a series of
events leading to the nuclear translocation of IFN regulatory factor 3
(IRF3), which – together with NFκB – is the major activator of IFNβ
expression. By binding to p300/CBP, E1A of Ad2/5 interferes with IRF3
activity, thereby blocking IFNβ expression. The lack of IFNβ expression
in Ad2-infected cells is consistent with the absence of downstream
ISGs. However, sequestration of p300/CBP also allows Ad2/5-E1A to
inhibit expression from ISGs through interference with the STAT-
containing ISGF3 transcription factor (Ackrill et al., 1991; Bhattacharya
et al., 1996; Juang et al., 1998; Kalvakolanu et al., 1991). So why cannot
Ad12-E1A inhibit IFNβ and ISG expression? One answer may be that
E1A from Ad2/5 and Ad12 exhibit differences in their respective
binding to p300. Amino acids 1–29 of Ad12 E1A are alone sufﬁcient to
bind p300 (Lipinski et al., 1999) and also harbour a trans-activating
function, which is missing in Ad2/5 E1A (Lipinski et al., 1997). Thus, it
has been suggested that Ad2/5 E1A and Ad12 E1A may engage in
different p300-containing complexes. Alternative mechanisms for the
observed induction of IFNβ expression are also possible. When
expressed in the absence of other viral proteins, the small virus-
associated RNAs (VA RNAI and II) can establish an antiviral state by
activation of IFNβ (Weber et al., 2006). Surprisingly, this does not
include activation of IRF3 (Weber et al., 2006). Moreover, Ad12 was
previously shown to enhance IFNβ expression in human embryo
kidney (HEK) in an E1B-dependent mechanism (Shiroki and Toth,
1988). Co-infection with Ad12 and Ad5 also showed increased IFNβ
expression, suggesting that the E1B activating function of Ad12
dominated over Ad5 E1A inhibition (Shiroki and Toth, 1988).
Consistent with these data, our previous microarray analyses of
adenovirus infected HeLa cells demonstrated an up regulation of
G1P2, IFIT2 and IFIT1 (Dorn et al., 2005) following Ad12 infection,
whereas no ISGs were activated during infectionwith Ad2 (Zhao et al.,
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i.e. at the same time as the onset of viral DNA replication, but declined
thereafter (Dorn et al., 2005). The delayed activation in IMR90 cells
and the transient activation in HeLa cells may reﬂect a more restricted
virus growth in IMR90 cells. In summary, these data are in agreement
with an inability of Ad12 to evade the antiviral defense of the host
thereby causing a less productive infection. Further studies are
required to elucidate the molecular mechanisms for this possibility.Materials and methods
Cell culture and virus infection
Human primary lung ﬁbroblast cells (IMR90), purchased from the
American Type Culture Collection, were cultured in Eagle's minimum
essential medium (MEM) with Earle's salt and GlutaMAX™ (GIBCO)
supplemented with 10% fetal bovine serum, 100 U/ml of penicillin,
100μg/ml of streptomycin, 0.1 mM nonessential amino acids, 1.5 g/l
sodium bicarbonate and 1.0 mM sodium pyruvate. The IMR90 cells
were synchronised as previously described (Zhao, Granberg, and
Pettersson, 2007) through continued cultivation for two days after
reaching conﬂuence. At this time, FACS analysis showed that about
94% of the cells were in the G0/G1 phase. The cells weremock-infected
or infected with Ad12 at a multiplicity of 100 particles per cell in
serum free MEM. After a 1 h adsorption at 37 °C, the medium was
replaced with MEM supplemented with 10% FBS and infected cells
were incubated at 37 °C. Infected cells were collected at 6, 12, 18, 24,
30, 36, 42, 54, 60 and 66 hpi (for the analysis of the progression of
Ad12 infection), or at 6, 18, 30 and 66 hpi (the microarray
experiments). Mock-infected cells were harvested at 6 hpi for both
analyses.Nucleic acid extraction and protein preparation
Total RNA was extracted using TRIZOL® Reagent (Invitrogen). The
quality and quantity of RNA preparations were determined by using
the RNA 6000 Nano LabChip kit and a Bioanalyser 400 (Agilent
technologies). DNA was prepared from cell pellets using the QIAamp
DNA Mini kit (QIAGEN) according to the manufacturer's protocol.
Quantities were measured using a Nanodrop ND-1000 spectro-
photometer (NanoDrop Technologies). Protein samples were pre-
pared by disrupting the cell pellet with a lysis buffer (1% SDS, 50 mM
Tris pH 7.4, 150 mM NaCl and 2 mM EDTA, 2 nM Pepstatin A, 10 nM
Aprotinin, 2 nM Lenpeptin and 100 nM PMSF). After a 5 min
centrifugation at 13000 rpm, the supernatant was collected.cDNA microarray hybridization and data analysis
Microarrays containing 46000 human cDNAs were obtained from
the DNA Microarray Core Facility at the Dept. of Biotechnology, Royal
Institute of Technology, Sweden. Labelling and hybridization
were performed according to the CyScribe Post-Labelling protocol
(GE Healthcare). For each experiment, 10 μg of total RNA was used to
generate amino allyl-labelled cDNA, which subsequently was coupled
with either Cy5 or Cy3 (GE Health Care, post-labelling protocol) and
hybridized to cDNA microarrays. Each RNA sample was analysed on
two arrays, of which one was “dye-swap” labelled. Thus, a total of 4
experiments were performed on each time point. Data collection and
normalization were done as described previously (Dorn et al., 2005;
Zhao et al., 2003; Zhao et al., 2007). Reporters with an average fold
value larger than 1.8 and a coefﬁcient of variation less than 60% in any
of the two time points were considered as signiﬁcant and used for
further interpretation.Quantitative real-time PCR (QRT-PCR)
The QRT-PCR assays were performed to (i) determine the
progression of the virus infection by monitoring the expression of
E1A and CCNE1, as well as the replication of viral DNA and (ii) to
validate selected microarray data. For the veriﬁcation of microarray
results, the QRT-PCR analyses were performed on the same sets of RNA
samples as used for the microarray hybridizations. All QRT-PCR
analyses were performed using SYBR green, except for the analysis of
IFIT1 and G1P2, which were done using TaqMan MGB probes from
Applied Biosystems. PCR primers were designed using Primer Express
(Applied Biosystems) and were, forward and reverse, respectively;
STAT1, ACCGCACCTTCAGTCTTTTCC and TGAACTGGACCCCTGTCTTCA;
STAT2, GAAAACTTTGACCCCCGAGAA and CGTGAAGCTGATGAT-
GTGCAG; IRF9, AGAGGATGCCATGCAGAACTG and GCTCCCAATG-
TCTGAATGGAC; IFNβ , TGCATTACCTGAAGGCCAAGG and
AATTGTCCAGTCCCAGAGGCA; Ad12 E1A, ATAGCACTTTGGATGGCGATG
and ATTACTCCTTCTGGAACCGCAC; β-actin, GAGCTACGAGCTGCCT-
GACG and GTAGTTTCGTGGATGCCACAGGACT; CCNE1, CTCCAGGAA-
GAGGAAGGCAA and TCGATTTTGGCCATTTCTTCA.
For cDNA synthesis, 2 μg of RNA was reverse-transcribed using
cMaster RT Kit (Eppendorf AG) according to the manufacturer's
protocol. QRT-PCRwas performed as described previously (Zhao et al.,
2003). An ABI PRISM 7900 HT sequence detection systemwas used for
the analysis.
Western blot analysis
20 μg protein from each cell lysate was mixed with 2× Laemmli
sample buffer (62.5 mM Tris–HCl pH 6.8, 25% glycerol, 0.01% BFB and
2% SDS), boiled for 5 min and then loaded on a 10% SDS-
polyacrylamide gel. After electrophoresis, the proteins were trans-
ferred to a polyvinylidene diﬂuoride membrane in a blotting chamber
(GE Healthcare). The membrane was blocked for 1 h at room
temperature, RTin ECL blocking agent (GE Healthcare) followed by
incubationwith the primary antibodies for 1 h at RT. Membranes were
washed three times for 10 min in Tris-buffered saline with 0.05%
Tween-20 (TBS-T) before the secondary antibody was added. After 1 h
incubation at RT themembranes werewashed four times for 10min in
TBS-T. To detect signals on the membranes an ECL kit (GE Healthcare)
was used followed by autoradiography. Monoclonal antibodies against
STAT2 (A-7, sc-1668) and polyclonal antibody against β-actin (I-19,
sc-1616) and IRF9 (H-143, sc-10793) were obtained from Santa Cruz
Biotechnology. Monoclonal antibody against STAT1 (9H2, mAb #9176)
was purchased from Cell Signalling.
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